Heghine Khachatryan on VWD: A Landmark in the History of Hematology
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, sreposted from Haematologica Journal on LinkedIn:
”A Landmark in the History of Hematology
One hundred years ago, the Finnish physician Erik Adolf von Willebrand published his seminal description of hereditary pseudohemophilia, a disorder that would later bear his name as von Willebrand disease.
This groundbreaking work was the first to clearly demonstrate that:
• inherited bleeding disorders may affect both sexes,
• the clinical phenotype can differ fundamentally from classical hemophilia, and
• family-based observation and pedigree analysis are critical to understanding disorders of hemostasis.
-The original genealogical diagram, shown here, represents more than a historical artifact—it laid the scientific foundation for modern concepts of primary hemostasis, platelet–vessel wall interaction, and the role of von Willebrand factor in coagulation.
-A century later, von Willebrand’s observations continue to inform contemporary diagnostics, molecular genetics, and individualized therapeutic strategies in bleeding disorders.
This milestone reminds us that careful clinical observation remains the cornerstone of scientific progress, even in the era of advanced genomics and precision medicine.”
Quoting Haematologica Journal‘s post:
”Landmark paper in Hematology: One hundred years ago the Finnish physician Erik Adolf von Willebrand published his landmark paper on hereditary pseudohemophilia in Documents of the Finnish Society of Medicine: he had discovered the disease that nowadays we universally known by his name.”
Read the full article here.
Article: The landmark contribution by Erik von Willebrand
Authors: Riitta Lassila, Erik Berntorp
Stay updated on all scientific advances with Hemostasis Today.
-
May 27, 2026, 17:51Nita Radhakrishnan: Post Graduate Institute of Child Health Receives WFH Data Quality Certification for Excellence
-
May 27, 2026, 17:51Fiona Robinson: What exactly Are Rebalancing Agents for Bleeding Aisorders?
-
May 27, 2026, 17:14Khurram Nasir: Can Earlier LDL-C Lowering Change the Trajectory of Cardiovascular Disease?
-
May 27, 2026, 17:09Yvonne Jongejan: Allele-Selective Silencing Therapy for VWD and Thrombotic Disorders
-
May 27, 2026, 16:58Catherine Moran: Important Step Forward as 1st WHO Resolution on Stroke Gets Adopted at WHA79
-
May 27, 2026, 16:08Heghine Khachatryan: Thrombosis in Oncology Remains a Major Healthcare Burden
-
May 27, 2026, 16:00Revealing Critical Gaps in Hemophilia Diagnosis and Access to Care in India – WFH
-
May 27, 2026, 16:00Melissa Hollo: Women Deserve Proactive Care, Not Reactive Care
-
May 27, 2026, 15:59Piotr Czempik: First Report of ROTEM Findings in Triple-Positive APS and Hageman Anomaly